Braskem S.A. (BAK): Assessing the Potential for a +49% Climb to $1.65

Key Takeaways

• The central target of $1.65 is the rounded arithmetic mean of the most recent analyst price targets, drawn from a set of six analyst targets spanning roughly $1.50 to $2.00.
• At a latest price near $1.11, reaching $1.65 would require a gain of about 49%, a very large move.
• The analyst consensus rating sits at "Sell" or "Moderate Sell," even though most remaining targets still sit above the collapsed share price.
• Targets have been slashed dramatically — HSBC cut its target to $1.50 from $6.50 in September 2026, citing growing equity risk from debt restructuring.
• The strongest support for a rebound is a completed debt restructuring and any recovery in petrochemical spreads; the biggest risk is the company's roughly $13 billion debt load and negative equity.
• For more detail, explore Major News, Today's Price Move, the Forecast, and Earnings pages for BAK.
• You can also follow Trending AI Robots to see which AI-driven strategies are generating activity across the market.

Analyst Price Targets and Consensus View

The analyst picture for BAK has deteriorated sharply. According to data tracked by S&P Global, six analysts now carry an average price target of roughly $1.66, within a narrow range of about $1.50 to $2.00, and the consensus rating is "Sell." This is a far cry from the $4 to $6 targets that prevailed a year ago.

The downgrades tell the story. In September 2026, HSBC cut BAK to Hold from Buy and slashed its target to $1.50 from $6.50, arguing that equity risks "have grown significantly" amid debt-restructuring news flow. Days earlier, UBS downgraded the stock to Sell from Neutral and reduced its target to $1.50 from $4, pointing to Chinese capacity additions that are set to keep petrochemical spreads under pressure. Bradesco BBI had already moved to an Underperform rating with a $1.50 target in April 2026.

Not all views were bearish in 2026. JPMorgan analyst Milene Carvalho upgraded the stock to Overweight with a $5.50 target in May 2026, citing tighter supply and improved governance, but that call predates the subsequent restructuring turmoil. Because targets now cluster tightly around $1.50 with a few near $2.00, the calculated mean is best represented as a clean $1.65 figure for this analysis. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Current Market Position and Path Toward the Target

The latest verified price for BAK is roughly $1.11, near the lower end of a 52-week range of about $0.74 to $5.40. Reaching the $1.65 central target implies upside of approximately 49%, which must be classified as a very large move. Even the lowest target of $1.50 sits about 35% above the current price — a reminder that the shares have collapsed faster than even the most cautious analysts have revised their numbers.

The path toward $1.65 runs squarely through the balance sheet. Braskem carries roughly $13 billion in total debt against a market capitalization of only a few hundred million dollars, with negative book value and an Altman Z-score in distress territory. A credible debt deal with creditors and shareholders — a process Reuters reports has been racing toward deadlines — would be the single most important step in restoring confidence. Absent that, any recovery in the share price is likely to remain fragile.

What Could Support a Move Toward the Target

• A completed debt restructuring that reduces leverage and removes near-term default risk could trigger a sharp re-rating of the equity.
• Petrochemical spreads have shown intermittent improvement, with Braskem reporting stronger profitability in its most recent quarter, aided by temporary spread gains and one-off tax credits.
• The company maintains a meaningful position in green polyethylene, a niche with structural growth appeal.
• With the stock down more than 55% over the past year and short interest near 8% of shares outstanding, a positive catalyst could force short-covering.

What Could Prevent the Target From Being Reached

• Braskem's debt load and negative equity leave little margin for error; an unsuccessful restructuring would pressure the shares further.
• Analysts warn that Chinese petrochemical capacity additions will keep global spreads suppressed, weighing on margins for an extended period.
• The lingering Alagoas geological event in Brazil remains a source of potential additional provisions and legal risk.
• The "Sell" consensus rating reflects a view that even the reduced $1.50-$2.00 targets may be optimistic if fundamentals weaken further.

Technical Levels and Market Structure

Technically, BAK remains in a steep long-term downtrend. The shares trade well below both the 50-day moving average near $1.60 and the 200-day moving average near $2.95. The $0.74 area, the 52-week low, is the key support level to defend, while the $1.50-$1.60 zone — where the 50-day average and the lowest analyst targets converge — represents the first meaningful resistance level. A sustained move above that band would be required before the $1.65 target comes into view.

Time Horizon and What Investors Should Monitor

Analyst price targets are generally set on a roughly 12-month research horizon, though individual firms rarely state a precise timeline and horizons can differ. For BAK, the near-term focus is the next earnings report scheduled for November 12, 2026, which should clarify cash flow and liquidity trends. Investors should also monitor the progress of the debt-restructuring negotiations, any further analyst target revisions, petrochemical spread data, and announcements on the Alagoas liabilities.

Leveraging AI Tools in My Analysis

In my own work tracking volatile names like this, Tickeron’s AI Daily Buy/Sell Signals have proven useful for spotting shifts in momentum without having to review every chart manually. The platform applies AI to scan thousands of stocks and ETFs, delivering Buy, Sell, or Hold signals based on technical behavior and market conditions. For a distressed stock facing rapid news flow, these signals can help highlight when trends may be changing and support more timely position management.

Final Assessment

Can BAK reach $1.65? The roughly 49% move required is very large, and it hinges almost entirely on a successful resolution of Braskem's debt problems. The supportive case rests on a completed restructuring, improved spreads, and a heavily shorted stock primed for a relief rally. The opposing case is equally clear: a roughly $13 billion debt load, negative equity, a "Sell" consensus, and persistent Chinese supply overhang. With analyst targets now tightly clustered between $1.50 and $2.00, the $1.65 central target is reachable only if the company first stabilizes its balance sheet — a precondition that remains unresolved.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Contributor

Sergey Savastiouk|Expert

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.

Notable companies

Industry description

Market Cap

High and low price notable news

Volume